Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to -$3.7 million.

  • Veracyte's Change in Account Payables fell 19421.22% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year increase of 4181.71%. This contributed to the annual value of -$4.3 million for FY2024, which is 311268.66% down from last year.
  • Veracyte's Change in Account Payables amounted to -$3.7 million in Q3 2025, which was down 19421.22% from -$4.0 million recorded in Q2 2025.
  • Over the past 5 years, Veracyte's Change in Account Payables peaked at $7.1 million during Q1 2025, and registered a low of -$4.0 million during Q2 2025.
  • In the last 5 years, Veracyte's Change in Account Payables had a median value of -$319000.0 in 2023 and averaged $16894.7.
  • Data for Veracyte's Change in Account Payables shows a peak YoY increase of 56113.99% (in 2025) and a maximum YoY decrease of 237345.68% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Veracyte's Change in Account Payables stood at $1.3 million in 2021, then tumbled by 62.82% to $477000.0 in 2022, then plummeted by 166.88% to -$319000.0 in 2023, then tumbled by 324.76% to -$1.4 million in 2024, then tumbled by 170.11% to -$3.7 million in 2025.
  • Its Change in Account Payables stands at -$3.7 million for Q3 2025, versus -$4.0 million for Q2 2025 and $7.1 million for Q1 2025.